These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20155596)

  • 1. What is diversion of supervised buprenorphine and how common is it?
    Winstock AR; Lea T; Sheridan J
    J Addict Dis; 2009 Jul; 28(3):269-78. PubMed ID: 20155596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR; Lea T; Sheridan J
    Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.
    Winstock AR; Lea T; Sheridan J
    Addiction; 2010 Feb; 105(2):335-42. PubMed ID: 20078490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified.
    Nielsen S; Dietze P; Dunlop A; Muhleisen P; Lee N; Taylor D
    Drug Alcohol Rev; 2007 Mar; 26(2):143-51. PubMed ID: 17364849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia.
    Winstock AR; Lea T
    Subst Use Misuse; 2010; 45(1-2):240-52. PubMed ID: 20025451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics.
    Winstock AR; Lea T; Jackson AP
    J Addict Dis; 2009; 28(1):57-63. PubMed ID: 19197596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
    Winstock AR; Lea T; Ritter A
    Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists.
    Lawrinson P; Roche A; Terao H; Le PP
    Drug Alcohol Rev; 2008 Jan; 27(1):47-53. PubMed ID: 18034381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
    Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
    Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' help-seeking behaviours for health problems associated with methadone and buprenorphine treatment.
    Winstock AR; Lea T; Sheridan J
    Drug Alcohol Rev; 2008 Jul; 27(4):393-7. PubMed ID: 18584389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995-2005.
    Sheridan J; Manning V; Ridge G; Mayet S; Strang J
    Addiction; 2007 Nov; 102(11):1824-30. PubMed ID: 17935587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment.
    Madden A; Lea T; Bath N; Winstock AR
    Drug Alcohol Rev; 2008 Nov; 27(6):671-8. PubMed ID: 19378450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland.
    Uosukainen H; Bell JS; Laitinen K; Tacke U; Ilomäki J; Turunen JH
    Int J Drug Policy; 2013 Sep; 24(5):492-7. PubMed ID: 23567099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
    Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
    Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
    Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
    Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
    Larance B; Carragher N; Mattick RP; Lintzeris N; Ali R; Degenhardt L
    Drug Alcohol Depend; 2014 Sep; 142():46-55. PubMed ID: 25015687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.
    Bell J; Byron G; Gibson A; Morris A
    Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
    Bell J; Mutch C
    Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Substitution treatment for opiate dependence: survey of community pharmacies in Aquitaine].
    Jeantaud I; Haramburu F; Bégaud B
    Therapie; 1999; 54(2):251-5. PubMed ID: 10394262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.